Shanghai RAAS Blood Products (002252) investor relations material

Executive summary

• Revenue for H1 2026 was ¥3.21 billion, down 18.79% year-over-year; net profit attributable to shareholders was ¥661 million, down 35.80% year-over-year.

• Gross margin for blood products was 35.37%, with core products experiencing margin pressure.

• Cash flow from operations was ¥405 million, down 45.20% year-over-year, reflecting lower sales and collections.

• The company continued to invest in R&D, with expenses up 32.49% to ¥134 million, focusing on innovative drugs and process upgrades.

• No interim dividend was declared; capital was allocated to R&D, digital transformation, and share buybacks.

Financial highlights

• Operating income: ¥3.21 billion, -18.79% year-over-year.

• Net profit attributable to shareholders: ¥661 million, -35.80% year-over-year.

• Basic and diluted EPS: ¥0.10, -35.48% year-over-year.

• Operating cash flow: ¥405 million, -45.20% year-over-year.

• Total assets at June 30, 2026: ¥37.46 billion, -0.86% from year-end 2025.

• Net assets: ¥32.41 billion, -0.13% from year-end 2025.

• R&D expenses: ¥134 million, up 32.49% year-over-year.

Outlook and guidance

• The company expects continued industry transformation and competitive pressure but aims for stable operations through digitalization, AI-driven efficiency, and innovation.

• Overseas expansion is a strategic focus, with 2026 marked as the 'go-global' year and international revenue growth targeted.

• Ongoing investment in innovative drugs and process upgrades is expected to support long-term growth.